Esperion Therapeutics

Esperion Therapeutics, Inc. is a public American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

Esperion Therapeutics, Inc.
Public
Traded asNASDAQ: ESPR
Russell 2000 Component
IndustryPharmaceutical
Founded2008 (2008)
Founder
  • Dr. Roger Newton
HeadquartersAnn Arbor, Michigan
Key people
Timothy M. Mayleben (president and CEO)
  • (US$26.1 million) (2013)
  • (US$11.7 million) (2012)
Total assets
  • US$78.3 million (2013)
  • US$7.31 million (2012)
WebsiteEsperion.com
Footnotes / references
financial information[1]:F-3,4

History

Pfizer acquired the original Esperion in 2004 for US$1,300,000,000 as a defensive move to prevent ETC-216 from falling into competitors' hands.[2]:165 Two years later, in 2006, Pfizer decided to kill the Esperion organization and development of ETC-216. In May 2008, Dr. Roger Newton, Esperion's founder and chief scientific officer, raised sufficient capital to acquire rights to ETC-1002 and Esperion from Pfizer, thereby leading to a second independent period for the company.[2]:165[3][4] In June 2013, Esperion became a public company again through an initial public offering.[5] As of April 2014, Esperion was traded on NASDAQ under the symbol "ESPR".[6]

Product candidates

The company's main product candidate, ETC-1002, is in phase II clinical development.

gollark: I'll add it to your psychological profile
gollark: Fascinating.
gollark: I mean, they sort of indirectly are, and at least evolved vaguely for that.
gollark: Fears are not there to protect you, fears are mostly just pretty stupid?
gollark: <@160279332454006795> cease C++ utilisation.

References
  1. "Esperion Therapeutics, Inc". EDGAR. Form 10-K. U.S. Securities and Exchange Commission. March 13, 2014. Commission File Number:001-35986.
  2. Li, Jie Jack (2009). Triumph of the Heart: The Story of Statins. Oxford University Press. ISBN 9780195323573.
  3. "History". Esperion Therapeutics. Archived from the original on April 29, 2012.
  4. Catherine Shaffer (2008). "Pfizer jettisons Esperion". Nat. Biotechnol. 26 (7): 724–725. doi:10.1038/nbt0708-724.
  5. Huggett, Brady (December 2013). "Burning Bright". Nat. Biotechnol. 31 (12). pp. 1068–71.
  6. "ESPR stock quote". NASDAQ. Retrieved April 22, 2014.

Further reading
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.